Loading...
XSTO
PLUN
Market cap81kUSD
, Last price  
SEK
Name

ProstaLund AB

Chart & Performance

D1W1MN
XSTO:PLUN chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
9.95%
Rev. gr., 5y
1.27%
Revenues
14m
-38.19%
7,654,0008,614,0009,613,00013,613,00014,612,00013,544,00013,567,00012,886,00012,465,00017,073,00017,411,00022,206,00013,725,000
Net income
-23m
L+33.05%
-561,000-4,645,000-7,786,000-9,373,000-11,974,000-16,894,000-12,950,000-10,728,000-10,041,000-7,919,000-11,303,000-17,010,000-22,631,000
CFO
-23m
L-5.08%
-2,605,000-3,875,000-10,834,000-9,750,000-14,407,000-16,114,000-11,893,000-9,115,000-8,581,000-5,804,000-16,202,000-23,801,000-22,591,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

ProstaLund AB (publ) develops and sells urological devices for the treatment of patients with benign prostatic hyperplasia (BPH) in Sweden and internationally. The company also offers CoreTherm, a heat treatment of BPH; and Gepan instill for the treatment of chronic bladder inflammation. Its products are used in hospitals and clinics. The company was founded in 1991 and is based in Lund, Sweden. ProstaLund AB (publ) is a subsidiary of Farstorps Gard Forvaltnings AB.
URL
https://www.prostalund.se/
IPO date
Oct 24, 2013
Employees
10
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT